SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                             CURRENT REPORT PURSUANT
                          TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


        Date of report (Date of earliest event reported): April 27, 2005


                         AMERICAN BIO MEDICA CORPORATION
             (Exact Name of Registrant as Specified in its Charter)

         New York                       0-28666                14-1702188
------------------------------- ------------------------  ----------------------
(State or Other Jurisdiction of (Commission File Number)      (IRS Employer
        Incorporation)                                    Identification Number)



      122 Smith Road, Kinderhook, NY                         12106
----------------------------------------                   ---------
(Address of Principal Executive Offices)                   (Zip Code)

       Registrant's telephone number, including area code: (800) 227-1243

                                 Not applicable
         (Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13c-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))



ITEM 3.01. NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR
STANDARD; TRANSFER OF LISTING.

            On April 27, 2005, the Company received a notice from the Nasdaq
Stock Market informing the Company that for the last 30 consecutive business
days, the bid price of the Company's common stock has closed below the minimum
$1.00 per share requirement for continued inclusion under Marketplace Rule
4310(c)(4).

            The letter stated that under Marketplace Rule 4310(c)(8)(d), the
Company will be provided with 180 calendar days, or until October 24, 2005, to
regain compliance with Marketplace Rule 4310(c)(4). To regain compliance,
anytime before October 24, 2005, the bid price of the Company's common stock
must close at $1.00 per share or more for a minimum of 10 consecutive business
days.


                                       2


                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                   AMERICAN BIO MEDICA CORPORATION (Registrant)


Dated: April 29, 2005              By: /s/ Keith E. Palmer
                                      ------------------------
                                       Keith E. Palmer
                                       Chief Financial Officer


                                       3